The first drugs for Alzheimer’s disease emerged in the 1990s, but since then there has been a wave of clinical trial failures, major companies pulling resources from neuroscience R&D, and progress.
A fascinating study in Europe finds that individuals who felt they had memory problems did in fact have measurable cognitive deficits. Scientists analyzed the spinal fluid to measure the levels of biomarkers associated with Alzheimer’s.
Swedish researchers find that cholinesterase inhibitors provide cognitive benefits and reduce mortality for up to five years after an Alzheimer’s diagnosis. One medication significantly reduced the risk of developing severe dementia.
Swiss researchers find that people with certain personality traits are protected against Alzheimer’s disease, including those who are less agreeable, had natural curiosity, and were nonconformists. Find out why.
Researchers in Florida find that robotic pet cats improve mood, behavior and cognition in older adults with mild to moderate dementia. Find out more.
Dr. Robert Przybelski has prescribed lecanemab to real-life patients, and discusses his experience prescribing and administering the treatment.
Scientists say restoring a brain protein, not removing amyloid plaques, should be the target of Alzheimer’s dementia therapies. The researchers said treatment might lie in normalizing the levels of a specific brain protein.
Now, a third new Alzheimer’s drug expected to be approved by the Food and Drug Administration (FDA),. The field of new drugs is beginning to show progress in the fight to slow the disease.
Researchers found in a study that people who developed dementia were more likely to have their credit rating drop at least two and a half years before the diagnosis. Some had problems managing their money up to six years before. Find out more.
The FDA has approved generic lecanemab (brand name Leqembi®). The new drug can slow the progression of Alzheimer’s. Two top doctors discuss the pros and cons.
TEEPA SNOW CARE VIDEO: Vascular dementia poses unique challenges to caregivers. Learn how vascular dementia differs from Alzheimer’s. See how to make life better, both for you and the one for whom you care.
People with dementia deserve dignity and have rights. Where do we draw the line between encouraging personal choices versus following what caregivers think is best? See Dr. Murray Raskin & Dr. Linda Teri offer experienced tips.
Heavy drinkers who have eight or more alcoholic drinks per week have increased risk of brain lesions called hyaline arteriolosclerosis, signs of brain injury that are associated with memory and thinking problems, according to a new study.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
This site was inspired by my Mom’s autoimmune dementia.
It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. It has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.
The site is dedicated to all those preserving the dignity of the community of people living with dementia.
Peter Berger, Editor